ATLANTA--(BUSINESS WIRE)--At the JPMorgan 26th Annual Health Care Conference in San Francisco, Sciele Pharma, Inc. (NASDAQ:SCRX), today announced that it will be launching during the first quarter of 2008 its new Sular® formulation, which was recently approved by the Federal Food & Drug Administration (FDA) in four dosage strengths: 8.5-milligram, 17-milligram and 25.5-milligram and 34-milligram dosages. In addition, the Company also plans to launch five new products in 2008: 120-milligram and 40-milligram fenofibrate doses for treatment of mixed dyslipidemia; Prandin® (repaglinide) for type II diabetes, and, upon FDA approval, PrandiMet® (repaglinide/metformin) also for type II diabetes; a head lice asphyxiation product upon FDA approval; and a new Women’s Health product.
